The key issue
A warning letter or inspection finding requires careful reading of dates, facility names and resolution status. The telehealth company, clinician, manufacturer and dispensing pharmacy can have different responsibilities. Verify each one independently. FDA-approved drugs and compounded drugs also have different regulatory statuses; a compounded drug is not FDA-approved.
Three concrete checks
1. Match the facility's legal name rather than a marketing nickname
Focus this check on: match the facility's legal name rather than a marketing nickname. Ask the dispensing pharmacist who can verify this point and where the current written record can be found. Collect: Exact licensed/legal name, jurisdiction, and official directory or registration entry, plus a dated response naming the responsible professional.
2. Review FDA or state board records
Focus this check on: review FDA or state board records. Ask the dispensing pharmacist who can verify this point and where the current written record can be found. Collect: A dated visit summary, relevant health history, actual medical instructions, and contact details for the treating team.
3. Distinguish an allegation, observation, corrective action and final determination
Focus this check on: distinguish an allegation, observation, corrective action and final determination. Ask the dispensing pharmacist who can verify this point and where the current written record can be found. Collect: Dated original documentation, the exact question asked, the organization answering, and any material limitation or unresolved discrepancy.
What to verify before acting
The product on the label, the dispensing facility, and the online marketing company may be three different things. Matching them is more informative than trusting a generic seal of approval.
Compounding is subject to federal and state conditions. Even a legitimate compounder cannot make its individual drug products FDA-approved by describing the facility as registered. State licensing records can establish licensing status, but do not prove an individual batch is safe. FDA registration of a 503B facility does not mean its drugs have FDA approval.
Document-by-document decision table
Compare the actual prescription, dispensing label, and pharmacy identity against the three questions below. Note the source and date of each answer, and explicitly mark anything still unknown.
| Question to resolve | Evidence to look for | How to log the result |
|---|---|---|
| 1. Match the facility's legal name rather than a marketing nickname | Exact licensed/legal name, jurisdiction, and official directory or registration entry, plus a dated response naming the responsible professional. | Record: answer / unknown / contradictory; date; who confirmed it. |
| 2. review FDA or state board records | A dated visit summary, relevant health history, actual medical instructions, and contact details for the treating team. | Record: answer / unknown / contradictory; date; who confirmed it. |
| 3. distinguish an allegation, observation, corrective action and final determination | Dated original documentation, the exact question asked, the organization answering, and any material limitation or unresolved discrepancy. | Record: answer / unknown / contradictory; date; who confirmed it. |
A worked example, not a treatment instruction
If a vial, label, and invoice disagree, an ordinary billing explanation may not resolve the clinical question. Preserve the materials and obtain an answer from the pharmacy and prescriber before use. This is an illustrative scenario, not a verified patient case.
If the answers do not agree
All three checks line up
If the legal pharmacy name, product description, and documented pharmacy response are consistent, save the dated source and move to the next appropriate clinical, billing or service step. Consistency is useful, but it is not proof that an individual treatment is indicated.
A key fact is absent
If the retailer uses only a brand nickname or declines to identify the actual dispensing facility, request clarification from the correct organization before paying, submitting more sensitive data, or acting on unfamiliar product instructions. Document the unanswered question.
Two records contradict one another
If the package, prescription, advertising claim or invoice describes a different product, facility or formulation, ask for a corrected written record and an explanation of which version controls. Avoid making medication or financial decisions from competing records.
Three follow-up questions worth sending
- Regarding “Match the facility's legal name rather than a marketing nickname”: what written evidence answers that question, and who is responsible for confirming it for the specific patient or account?
- Regarding “Review FDA or state board records”: what written evidence answers that question, and who is responsible for confirming it for the specific patient or account?
- Regarding “Distinguish an allegation, observation, corrective action and final determination”: what written evidence answers that question, and who is responsible for confirming it for the specific patient or account?
Keep a compact evidence file
Label photograph showing the pharmacy and product name, lot or dispensing identifiers when available, order number, relevant email and dated screenshots. Keep personal identifiers out of public review posts. Use a private folder or secure account, not a public social-media thread. A quick four-column log works well: claim or concern, source and date, confirmed / unknown, and responsible contact. This makes repeat calls easier and allows you to correct an earlier impression if new facts arrive.
Where this guide stops
Do not administer a product when its identity, integrity, strength, or directions are unclear; contact the responsible pharmacist and prescriber. A website cannot determine whether an individual compounded formulation is appropriate. A pharmacy license is not a product approval, an advertisement is not a prescription, and a shipping confirmation is not a release by a pharmacist. If a central claim cannot be checked, it is fair to leave it unresolved. There is no need to convert a lack of evidence into a definitive accusation or endorsement.
Related official reference: FDA: Legal Framework for 503A/503B Compounding. This background reference explains part of the general framework; it does not independently establish claims about any named affiliate or individual patient.
Source-checked background and limits
Check official licensing and product classification; FDA registration or a pharmacy license does not approve a compounded drug. FDA says semaglutide and tirzepatide are no longer on the relevant shortage lists, and routine compounding of copies faces statutory restrictions.
Primary-source guidance checked October 12, 2026. These sources establish general background only; they do not verify any commercial provider, patient-specific recommendation, insurance benefit, or quoted price.
Sources for further checking
The links below provide general regulatory, medication-safety or consumer-protection context. They do not verify or endorse the practices, services, prices or clinical decisions of a particular affiliate partner.
- FDA: Concerns with Unapproved GLP-1 Drugs
- FDA: GLP-1 Compounding Policy
- FDA: BeSafeRx and Online Pharmacies
Compare available care options
Our comparison pages list participating partners. Check the provider's current terms and medical qualifications directly; recommendations are not prescriptions.
Compare participating providers →We may earn a commission when readers use certain partner links and complete qualifying actions. Affiliate compensation does not establish safety, eligibility or value.